The SGLT2 Inhibitor Canagliflozin Reduces Atherosclerosis by Enhancing Macrophage Autophagy

被引：0
|
作者：
Hongping Chen
Da Teng
Bowen Xu
Chunxiao Wang
Hua Wang
Wenjuan Jia
Lei Gong
Haibin Dong
Lin Zhong
Jun Yang
机构：
[1] Qingdao University,School of Medicine
[2] Yuhuangding Hospital,Department of Cardiology
[3] The Fourth School of Clinical Medicine of Qingdao University,undefined
[4] Binzhou Medical University,undefined
来源：
Journal of Cardiovascular Translational Research | 2023年 / 16卷
关键词：
SGLT2 inhibitor; Macrophage; Autophagy; Atherosclerosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：999 / 1009
页数：10
相关论文
共 50 条
  • [31] Novel therapeutic option in type 2 diabetes patients - practical experience with canagliflozin, SGLT2 inhibitor
    Milczarczyk, Alicja
    Franek, Edward
    Cichocka, Edyta
    Gumprecht, Janusz
    CLINICAL DIABETOLOGY, 2015, 4 (05): : 204 - 209
  • [32] Dapagliflozin, an SGLT2 inhibitor, for diabetes
    Hanefeld, Markolf
    Forst, Thomas
    LANCET, 2010, 375 (9733): : 2196 - 2198
  • [33] Update on SGLT2 Inhibitor Warning
    Voelker, Rebecca
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 315 (03): : 243 - 243
  • [34] Clinical prospective of SGLT2 inhibitors in atherosclerosis
    Capuano, Annalisa
    Clementi, Emilio
    Paolisso, Giuseppe
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [35] Administration of a short (12-nucleotide)antisense inhibitor targeting SGLT2 specifically reduces SGLT2 levels and attenuates hyperglycemia in animals
    Monia, Brett P.
    Wancewicz, Edward V.
    Watts, Lynnetta
    Samadzadeh, Laura
    Matson, John
    Geary, Richard
    Bhanot, Sanjay
    Siwkowski, Andrew
    DIABETES, 2006, 55 : A471 - A471
  • [36] Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin
    B Haas
    N Eckstein
    V Pfeifer
    P Mayer
    M D S Hass
    Nutrition & Diabetes, 2014, 4 : e143 - e143
  • [37] Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin
    Haas, B.
    Eckstein, N.
    Pfeifer, V.
    Mayer, P.
    Hass, M. D. S.
    NUTRITION & DIABETES, 2014, 4 : e143 - e143
  • [38] The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma
    Jojima, Teruo
    Wakamatsu, Sho
    Kase, Masato
    Iijima, Toshie
    Maejima, Yuko
    Shimomura, Kenju
    Kogai, Takahiko
    Tomaru, Takuya
    Usui, Isao
    Aso, Yoshimasa
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (20)
  • [39] SGLT2 Inhibitor Canagliflozin Alleviates High Glucose-Induced Inflammatory Toxicity in BV-2 Microglia
    Lee, Ching-Tien
    Lin, Kun-Der
    Hsieh, Cheng-Fang
    Wang, Jiz-Yuh
    BIOMEDICINES, 2024, 12 (01)
  • [40] THE SGLT2 INHIBITOR CANAGLIFLOZIN SHOWN TO BE SUPERIOR COMPARED WITH GLIMEPIRIDE AS ADD ON THERAPY TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES
    Idris, Iskandar
    DIABETES OBESITY & METABOLISM, 2016, 18 (09): : 949 - 949
12345